MASCC 2012
Home
General Information
Scientific Information
Registration
Accommodation
Support and Exhibition
Useful Links
Bookmark and Share
MASCC/ISOO 2012 Symposium
Scientific Program
Abstracts Presentation Information
ISOO Course
Symposium Workshops
Symposium Speakers
CME & CNE Accreditation and MASCC/ISOO 2012
Study Groups
Febrile Neutropenia Sessions
Abstract Submission
Symposium Topics
Patient Seminar
Meet the MASCC/ISOO Speakers

CME & CNE Accreditation and MASCC/ISOO 2012 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and MASCC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians. 

Credit Designation

The Postgraduate Institute for Medicine designates this live activity for a maximum of 16.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Nursing Continuing Education

 Credit Designation

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 16.75 contact hours is provided by Postgraduate Institute for Medicine.

 

Important information

Kindly note the the following Sessions/Presentations are NOT CME/CE Accredited:

  • Febrile Neutropenia - New Concepts in the Use of Granulocyte Stimulating Factors - Friday, June 29 - 10:00-11:30 - Session not accredited
  • Parallel Session - Antiemetics 1 - Report on the Nausea Workshop and Related Issues - ROLAPITANT, A NOVEL NK-1 RECEPTOR ANTAGONIST, FOR THE PREVENTION OF NAUSEA IN SUBJECTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY (HEC), D. Chua, A. Poma, M.L. Hedley, Hong Kong S.A.R., USA - Presentation not accredited due to conflict of interest

  • Oral Presentations - Proffered Papers I - Febrile Neutropenia- A RANDOMIZED, NON-INFERIORITY STUDY OF BALUGRASTIM AND PEGFILGRASTIM IN BREAST CANCER PATIENTS RECEIVING MYELOSUPPRESSIVE THERAPY , O. Gladkov, V. Moiseyenko, I.N. Bondarenko, Y. Shparyk, S. Barash, J.M. Herpst, U. Mueller, Russia, Ukraine, USA, German - Presentation not accredited due to conflict of interest

  • Oral Presentations - Proffered Papers I - Febrile Neutropenia- EFFICACY AND SAFETY OF BALUGRASTIM COMPARED WITH PEGFILGRASTIM IN PATIENTS WITH BREAST CANCER WHO ARE RECEIVING CHEMOTHERAPY, C. Volovat, O.A. Gladkov, I.M. Bondarenko, S. Barash, A. Buchner, N. Avisar, P. Bias, U. Mueller, Romania, Russia, Ukraine, USA, Germany, Israel - Presentation not accredited due to conflict of interest

  • Oral Presentations - Proffered Papers I - Febrile Neutropenia- A RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROL, MULTICENTER, DOSE FINDING STUDY OF LIPEGFILGRASTIM IN BREAST CANCER PATIENTS RECEIVING MYELOSUPPRESSIVE THERAPY, A. Buchner, P. Bias, M. Kaufmann, U. Mueller, Germany - Presentation not accredited due to conflict of interest

  •  Plenary Session –Emerging and Under-Addressed Issues in Supportive Care - MOLECULAR PREDICTORS IN SUPPORTIVE CARE, S.Sonis, USA - Presentation not accredited due to conflict of interest

  • Parallel Session - Antiemetics 2 – New Agents and New Studies - AN EVALUATION OF THE DEGREE OF NEUROKININ-1 RECEPTOR OCCUPANCY IN THE HUMAN BRAIN AFTER NETUPITANT SINGLE DOSES ADMINISTRATION, G. Rossi, S. Olivari Tilola, C. Rudengren, M. Palmas, Switzerland, Sweden - Presentation not accredited due to conflict of interest

  • Parallel Session - Antiemetics 2 – New Agents and New Studies  - EFFICACY AND SAFETY OF ROLAPITANT FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN SUBJECTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY, D. Chua, A. Poma, M.L. Hedley, Hong Kong S.A.R., USA - Presentation not accredited due to conflict of interest

  • Proffered Papers II - Assessment and Perceptions in Supportive Care – COST OF SKELETAL COMPLICATIONS FROM BONE METASTASES (BM): RESULTS FROM A RETROSPECTIVE EUROPEAN STUDY, O. Gunther, J.-J. Body, H. Sleeboom, G. Hechmati, J. Pereira, N. Maniadakis, E. Terpos, Y.-P. Acklin, J. Finek, R. von Moos, UK, Belgium, The Netherlands, Switzerland, Portugal, Greece, Czech Republic - Presentation not accredited due to conflict of interest

  • Proffered Papers IV - Oral, Cutaneous, Fatigue and Cachexia Issues – EFFECT OF ENOBOSARM ON PHYSICAL FUNCTION IN CANCER PATIENTS WITH < OR ≥5% WEIGHT LOSS IN A PHASE IIB TRIAL, S.T. Dodson, M.A. Johnston, M.L. Hancock, M.S. Steiner, J. Dalton, USA - Presentation not accredited due to conflict of interest

  • Proffered Papers IV - Oral, Cutaneous, Fatigue and Cachexia Issues – PREVALENCE AND IMPACT OF HYPOGONADISM IN CANCER PATIENTS WITH MUSCLE WASTING IN A PHASE IIB ENOBOSARM TRIAL, S.T. Dodson, A. Dobs, M.A. Johnston, M.L. Hancock, R.A. Morton, M.S. Steiner, J. Dalton, USA - Presentation not accredited due to conflict of interest

     

Educational Objectives

After completing this activity, the participant should be better able to:

  • After completing this activity, the participant should be better able to:
    Discuss the risk for delayed CINV with HEC and MEC regimens and prescribe optimal combinations of antiemetic agents to reduce the risk of this adverse event
  • Assess and stage oral mucositis in patients undergoing chemotherapy or radiation therapy
  • Select the best strategy for managing TKI-associated gastrointestinal effects
  • Discuss the risks for skin toxicities associated with EGFR inhibitors
  • Formulate strategies for alleviating acneiform rash in patients undergoing EGFR therapy
  • Identify patients at risk for osteonecrosis of the jaw associated with bisphosphonate therapy
  • Evaluate when prophylaxis with a LMWH or other anticoagulant is appropriate to reduce the risk of VTE in hospitalized cancer patients
  • Practice more effective management of chronic cancer pain and breakthrough pain in patients
  • Identify and manage depression and other psychosocial effects of cancer in patients
  • Assist patients with negotiating through and handling survivorship issues
  • For registered nurses: Provide appropriate care and counsel for patients and their families 
  •  

Disclosure of Unlabeled Use

 
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. PIM, MASCC/ISOO, Eisai, Inc. and Amgen do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, MASCC/ISOO, Eisai, Inc. or Amgen. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Please click here for further information regarding faculty disclosure of Conflict of Interest

 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to

serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations.

 

CERTIFICATES OF CME AND CE CREDIT

Certificates for participation in CME & CE certified sessions will be issued directly from the accredited provider, Postgraduate Institute for Medicine. In order to receive credit you must complete an online evaluation form. You will be able to complete an evaluation form onsite, at the CME & CE Station at the Registration Area, or alternatively fill in the online form that will be sent to your email up to 10 days after the meeting.

Participants must provide a valid mailing address upon completion of the form. Requests for credit will be mailed to participants approximately 4-6 weeks post conference. For further information, please contact the Registration Desk. 

CERTIFICATE OF ATTENDANCE

Certificates of Attendance will be available at the pre-paid registration stations from Friday, June 29th at 14:30 until the end of sessions on Saturday, June 30th. Participants are requested to scan their name badge

at the machine and the certificate will automatically be printed with the participant’s name.

 

ATTENDANCE TRACKING REPORT

Self scanning devices are placed in the registration area. You may approach the scanners and self-scan your badge in order to record your attendance. Only participants who have recorded their attendance will receive a  report tracking their daily attendance time-frame at the Symposium from the Secretariat after the Symposium.

Scanning your badge on a daily basis upon arrival and departure is necessary in order to receive a full and detailed report of your attendance. Please make sure your email address is updated when scanning your badge. If you wish to update your email address please approach the Registration Desk.